AstraZeneca’s New Study on Benralizumab: Potential Game-Changer for Eosinophilic Asthma Treatment?

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is currently recruiting participants for a clinical study titled ‘BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist.’ The study aims to assess the efficacy and safety of benralizumab as an add-on therapy for patients with uncontrolled eosinophilic asthma, compared to conventional escalation to high-dose ICS-LABA treatment.

The intervention being tested is benralizumab, a subcutaneous injection administered as an add-on therapy to medium-dose ICS-LABA. The goal is to improve asthma control in patients who do not respond adequately to current treatments.

This is a randomized, double-blind, active-controlled study with a parallel group design. Participants are randomly assigned to receive either medium-dose ICS-LABA with benralizumab or high-dose ICS-LABA with a placebo. The study employs quadruple masking to ensure unbiased results, targeting treatment as its primary purpose.

The study began on March 28, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on June 24, 2025, indicating ongoing recruitment and progress.

The outcome of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, particularly if benralizumab proves to be a superior treatment option. This could position AstraZeneca favorably against competitors in the respiratory treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.